Dr. Alon Lazarus is a Biotech Investment Manager for Arkin Holdings’ Pharma Division. He is a member of the Board of several of its pharmaceutical companies, including Werewolf Therapeutics, Photys Therapeutics, Auron Therapeutics, Bluejay Therapeutics, Lutris Pharma and Redpin Therapeutics. He previously served as a board member of Keros Therapeutics.

Prior to joining Arkin, Dr. Lazarus worked for the Healthcare Business Development Department of Yissum—the Research & Development arm of the Hebrew University and as an analyst for the University’s Integra Holdings. Alon earned both a Ph.D. in Molecular Biology and an MBA from the Hebrew University of Jerusalem in Israel.